Crystal Structure of Recombinant Human Tissue Kallikrein at 2.0 A Resolution

Overview

Journal Protein Sci

Specialty Biochemistry

Date 1998 May 6

PMID 9568894

Citations 8

Authors

B A Katz

B Liu

M Barnes

E B Springman

Affiliations

Soon will be listed here.

Abstract

Human tissue kallikrein, a trypsin-like serine protease involved in blood pressure regulation and inflammation processes, was expressed in a deglycosylated form at high levels in Pichia pastoris, purified, and crystallized. The crystal structure at 2.0 A resolution is described and compared with that of porcine kallikrein and of other trypsin-like proteases. The active and S1 sites (nomenclature of Schechter I, Berger A, 1967, Biochem Biophys Res Commun 27:157-162) are similar to those of porcine kallikrein. Compared to trypsin, the S1 site is enlarged owing to the insertion of an additional residue, cis-Pro 219. The replacement Tyr 228 --> Ala further enlarges the S1 pocket. However, the replacement of Gly 226 in trypsin with Ser in human tissue kallikrein restricts accessibility of substrates and inhibitors to Asp 189 at the base of the S1 pocket; there is a hydrogen bond between O delta1Asp189 and O gammaSer226. These changes in the architecture of the S1 site perturb the binding of inhibitors or substrates from the modes determined or inferred for trypsin. The crystal structure gives insight into the structural differences responsible for changes in specificity in human tissue kallikrein compared with other trypsin-like proteases, and into the structural basis for the unusual specificity of human tissue kallikrein in cleaving both an Arg-Ser and a Met-Lys peptide bond in its natural protein substrate, kininogen. A Zn+2-dependent, small-molecule competitive inhibitor of kallikrein (Ki = 3.3 microM) has been identified and the bound structure modeled to guide drug design.

Citing Articles

Novel Mutations Cause Hypomaturation Amelogenesis Imperfecta.

Lee Y, Zhang H, Seymen F, Kim Y, Kasimoglu Y, Koruyucu M J Pers Med. 2022; 12(2).

PMID: 35207639 PMC: 8878363. DOI: 10.3390/jpm12020150.

Development of Chemical Tools to Monitor Human Kallikrein 13 (KLK13) Activity.

Gruba N, Bielecka E, Wysocka M, Wojtysiak A, Brzezinska-Bodal M, Sychowska K Int J Mol Sci. 2019; 20(7).

PMID: 30925705 PMC: 6479877. DOI: 10.3390/ijms20071557.

Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Prassas I, Eissa A, Poda G, Diamandis E Nat Rev Drug Discov. 2015; 14(3):183-202.

PMID: 25698643 DOI: 10.1038/nrd4534.

Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Goettig P, Magdolen V, Brandstetter H Biochimie. 2010; 92(11):1546-67.

PMID: 20615447 PMC: 3014083. DOI: 10.1016/j.biochi.2010.06.022.

Crystallization and preliminary crystallographic studies of human kallikrein 7, a serine protease of the multigene kallikrein family.

Fernandez I, Standker L, Forssmann W, Gimenez-Gallego G, Romero A Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007; 63(Pt 8):669-72.

PMID: 17671364 PMC: 2335154. DOI: 10.1107/S1744309107031764.

References

Geiger R, Stuckstedte U, Clausnitzer B, Fritz H . Progressive inhibition of human glandular (urinary) kallikrein by human serum and identification of the progressive antikallikrein as alpha 1-antitrypsin (alpha 1-protease inhibitor). Hoppe Seylers Z Physiol Chem. 1981; 362(3):317-25. DOI: 10.1515/bchm2.1981.362.1.317. View

Katz B, Clark J, Jenkins T, Johnson C, Ross M, Luong C . Design of potent selective zinc-mediated serine protease inhibitors. Nature. 1998; 391(6667):608-12. DOI: 10.1038/35422. View

Bode W, Chen Z, Bartels K, KUTZBACH C, Schmidt-Kastner G, Bartunik H . Refined 2 A X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J Mol Biol. 1983; 164(2):237-82. DOI: 10.1016/0022-2836(83)90077-3. View

Kato H, Enjyoji K, Miyata T, Hayashi I, Oh-ishi S, Iwanaga S . Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: direct evidence for liberation of bradykinin by rat glandular kallikreins. Biochem Biophys Res Commun. 1985; 127(1):289-95. DOI: 10.1016/s0006-291x(85)80157-1. View

Blevins R, Tulinsky A . Comparison of the independent solvent structures of dimeric alpha-chymotrypsin with themselves and with gamma-chymotrypsin. J Biol Chem. 1985; 260(15):8865-72. View

Fiedler F, Hinz H, Lottspeich F . Individual reaction steps in the release of kallidin from kininogen by tissue kallikrein. Adv Exp Med Biol. 1986; 198 Pt A:283-9. DOI: 10.1007/978-1-4684-5143-6_39. View

Remington S, Woodbury R, REYNOLDS R, Matthews B, NEURATH H . The structure of rat mast cell protease II at 1.9-A resolution. Biochemistry. 1988; 27(21):8097-105. DOI: 10.1021/bi00421a019. View

Angermann A, Bergmann C, Appelhans H . Cloning and expression of human salivary-gland kallikrein in Escherichia coli. Biochem J. 1989; 262(3):787-93. PMC: 1133342. DOI: 10.1042/bj2620787. View

Meyer E, Cole G, Radhakrishnan R, Epp O . Structure of native porcine pancreatic elastase at 1.65 A resolutions. Acta Crystallogr B. 1988; 44 ( Pt 1):26-38. DOI: 10.1107/s0108768187007559. View

10.

Schechter I, Berger A . On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967; 27(2):157-62. DOI: 10.1016/s0006-291x(67)80055-x. View

11.

GERATZ J . Synthetic inhibitors and ester substrates of pancreatic kallikrein. Experientia. 1969; 25(5):483-4. DOI: 10.1007/BF01900768. View

12.

Morrison J . Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta. 1969; 185(2):269-86. DOI: 10.1016/0005-2744(69)90420-3. View

13.

Krieger M, Kay L, Stroud R . Structure and specific binding of trypsin: comparison of inhibited derivatives and a model for substrate binding. J Mol Biol. 1974; 83(2):209-30. DOI: 10.1016/0022-2836(74)90388-x. View

14.

Huber R, KUKLA D, Bode W, Schwager P, Bartels K, Deisenhofer J . Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol. 1974; 89(1):73-101. DOI: 10.1016/0022-2836(74)90163-6. View

15.

Bode W, Schwager P . The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J Mol Biol. 1975; 98(4):693-717. DOI: 10.1016/s0022-2836(75)80005-2. View

16.

Cha S . Tight-binding inhibitors-I. Kinetic behavior. Biochem Pharmacol. 1975; 24(23):2177-85. DOI: 10.1016/0006-2952(75)90050-7. View

17.

Tidwell R, GERATZ J, DANN O, Volz G, Zeh D, LOEWE H . Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J Med Chem. 1978; 21(7):613-23. DOI: 10.1021/jm00205a005. View

18.

Schachter M . Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions. Pharmacol Rev. 1979; 31(1):1-17. View

19.

Laskowski Jr M, Kato I . Protein inhibitors of proteinases. Annu Rev Biochem. 1980; 49:593-626. DOI: 10.1146/annurev.bi.49.070180.003113. View

20.

Figueiredo A, Salgado A, Siqueira G, Velloso C, BERALDO W . Rat uterine contraction by kallikrein and its dependence on uterine kininogen. Biochem Pharmacol. 1990; 39(4):763-7. DOI: 10.1016/0006-2952(90)90156-f. View